四川大学华西医院/生物治疗国家重点实验室研究员，博士生导师，入选国家级青年人才。主要从事细胞程序性死亡途径中创新药物靶标的发现及其治疗银屑病、玫瑰痤疮、SLE等自身免疫疾病的基因治疗技术研发。近5年在国内外高水平期刊上发表学术论文60余篇，总被引3000余次，H-Index为45；申请发明专利12项，授权8项；主持国家“863”计划、国家自然科学基金等国家级项目6项；获得四川省科技进步一等奖、中华医学会青年科技奖等。
中华医学会皮肤病学分会实验学组委员；四川省药学会药物化学专委会委员
2021年中华医学会青年科技奖（1/9）；2019年四川省科技进步一等奖（3/10）
(1) Icaritin Represses Autophagy to Promote Colorectal Cancer Cell Apoptosis and Sensitized LowTemperature Photothermal Therapy via Targeting HSP90-TXNDC9 Interactions, Advanced Science, 2025, 12(20) 2412953.
(2) Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials , Signal Transduction and Targeted Therapy, 2023, 8: 355.
(3) Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fusedspirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma, Acta Pharmaceutica Sinica B, 2020, 10(8): 1492-1510.
(4) Organellar quality control crosstalk in aging-related disease: Innovation to pave the way , Aging Cell, 2025, 24(1): e14447.
(5) Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells, Journal of Medicinal Chemistry, 2020, 63(7): 3678-3700.
研究生部公众号
川公网安备51010702002012